You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCG unresponsive

Showing 1 - 25 of 597
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bladder Cancer Trial in Nara, Okayama (FE 999326)

Recruiting
  • Bladder Cancer
  • FE 999326
  • Nara, Japan
  • +1 more
Jan 19, 2023

Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma Trial in Tampa (Adoptive Cell Therapy with Tumor-infiltrating

Recruiting
  • Urothelial Carcinoma
  • Non-Invasive Bladder Urothelial Carcinoma
  • Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
  • Tampa, Florida
    Moffitt Cancer Center
Mar 2, 2023

NMIBC Trial in Beijing (RC48-ADC in Combination with gemcitabine)

Recruiting
  • NMIBC
  • RC48-ADC in Combination with gemcitabine
  • Beijing, Beijing, China
    Peking University First Hosptital
Jul 10, 2023

Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I Trial in Los Angeles (Pharmacokinetic Study,

Not yet recruiting
  • Recurrent Bladder Carcinoma
  • +2 more
  • Pharmacokinetic Study
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Jan 31, 2023

Urothelial Carcinoma, Bladder Cancer Trial in United States (drug, radiation, biological)

Recruiting
  • Urothelial Carcinoma
  • Bladder Cancer
  • Durvalumab (Cohort 1-3)
  • +7 more
  • Phoenix, Arizona
  • +10 more
Jan 11, 2023

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8

Not yet recruiting
  • High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • +3 more
  • PD-L1/IDO Peptide Vaccine
  • Pembrolizumab
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Apr 24, 2023

Superficial Bladder Cancer Trial in United States (EG-70)

Recruiting
  • Superficial Bladder Cancer
  • Tucson, Arizona
  • +7 more
May 11, 2022

Bladder Carcinoma in Situ (CIS) Trial (ONCOFID P-B (PACLITAXEL-HYALURONIC ACID))

Recruiting
  • Bladder Carcinoma in Situ (CIS)
  • ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
  • New Orleans, Louisiana
    Ochsner Clinic Foundation
Jan 18, 2023

Bladder Cancer Trial in United States (N-803 and BCG, N-803)

Recruiting
  • Bladder Cancer
  • Anchorage, Alaska
  • +31 more
Oct 26, 2022

Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG Trial in Canada, United States (TLD-1433 Bladder infusion and

Recruiting
  • Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
  • TLD-1433 Bladder infusion and Photodynamic Therapy
  • Bala-Cynwyd, Pennsylvania
  • +10 more
May 6, 2022

Superficial Bladder Cancer Trial in United States (ADSTILADRIN)

Active, not recruiting
Has Results
  • Superficial Bladder Cancer
  • ADSTILADRIN
  • Gilbert, Arizona
  • +33 more
Dec 2, 2022

Bladder Cancer Trial (pembrolizumab)

Active, not recruiting
  • Bladder Cancer
  • Pembrolizumab
  • +2 more
  • (no location specified)
Oct 11, 2022

Urinary Bladder Tumors Trial in Worldwide (Nivolumab, BCG, BMS-986205)

Completed
  • Urinary Bladder Neoplasms
  • Nivolumab
  • +2 more
  • Los Angeles, California
  • +88 more
Jan 24, 2023

Bladder Cancer Trial in China (HX008)

Recruiting
  • Bladder Cancer
  • Wuhan, Hubei, China
  • +4 more
Jan 31, 2021

Non Muscle Invasive Bladder Cancer Trial in Korea, Republic of, United States (CG0070, Pembrolizumab Injection,

Recruiting
  • Non Muscle Invasive Bladder Cancer
  • CG0070
  • +2 more
  • Phoenix, Arizona
  • +20 more
Jun 16, 2022

Bladder Carcinoma in Situ (CIS) Trial in Italy, Spain (ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID))

Completed
  • Bladder Carcinoma in Situ (CIS)
  • ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)
  • Milan, Mi, Italy
  • +4 more
Mar 13, 2021

QUILT-3.032 and of QUILT-2.005

Terminated
  • Pharmacokinetics
  • BCG in Combination with N-803
  • N-803 alone
  • Los Angeles, California
  • +5 more
Jan 20, 2021

Non Muscular Invasive Bladder Cancer Trial in Worldwide (CG0070, n-dodecyl-B-D-maltoside)

Recruiting
  • Non Muscular Invasive Bladder Cancer
  • CG0070
  • n-dodecyl-B-D-maltoside
  • Homewood, Alabama
  • +58 more
Jun 16, 2022

Urinary Bladder Tumors Trial in United States (E7766)

Withdrawn
  • Urinary Bladder Neoplasms
  • Gilbert, Arizona
  • +8 more
Dec 10, 2020

Bladder Cancer, Bladder Tumor, Bladder Tumors Trial in Hanover, New York, Philadelphia (Synergo® RITE + MMC)

Terminated
  • Bladder Cancer
  • +10 more
  • Synergo® RITE + MMC
  • Hanover, Maryland
  • +3 more
Apr 14, 2020

High-risk NMIBC Trial (SHR-1501)

Recruiting
  • High-risk NMIBC
  • Beijing, Beijing, China
    Peking University First Hospital
Nov 28, 2022

Bladder Urothelial Carcinoma In Situ, Infiltrating Bladder Mixed Carcinoma, Stage 0a Bladder Cancer AJCC v8 Trial in Guam,

Recruiting
  • Bladder Urothelial Carcinoma In Situ
  • +4 more
  • Gemcitabine Hydrochloride
  • Pembrolizumab
  • Birmingham, Alabama
  • +379 more
Aug 23, 2022

Bladder Cancer Trial in United States (Atezolizumab, Bacille Calmette-Guérin)

Terminated
Has Results
  • Bladder Cancer
  • Stanford, California
  • +7 more
Sep 29, 2021

Non-muscle-invasive Bladder Cancer Trial (Avelumab, Radiotherapy)

Not yet recruiting
  • Non-muscle-invasive Bladder Cancer
  • (no location specified)
May 14, 2019

Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial

Active, not recruiting
  • Recurrent Bladder Urothelial Carcinoma
  • +3 more
  • Daphne, Alabama
  • +271 more
Jul 20, 2022